When will Apelvis be available in China?

Alpelisib (Alpelisib), known as Alpelisib in English, is an innovative drug for malignant tumors, especially for the treatment of breast cancer. The drug has been approved by the FDA in the United States in 2019 for the treatment of specific types of breast cancer, namely advanced or metastatic breast cancer that is hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, and has PIK3CA gene mutations. This drug, used in combination with fulvestrant, provides patients with a new treatment option.

As of now, Apelis has not been launched in China. Although the drug has been widely used and recognized abroad, in China, because it needs to go through a series of strict approval processes, including clinical trials, efficacy evaluation, safety evaluation, etc., the time to market will be delayed. Currently, the drug is undergoing marketing review in China, which means it will take some time before it can officially enter the Chinese market.

Since Apelvis has not yet been launched in China, patients cannot directly purchase this drug in China. This brings some trouble to patients, because they need to purchase drugs abroad or obtain drugs through other channels. However, these methods are not only expensive, but also carry the risk of purchasing counterfeit medicines. Therefore, patients and doctors are looking forward to Apelix being launched in China as soon as possible so that more patients can benefit from this innovative drug.

To sum up, Apelis has not yet been launched in China, but is under review for listing. Patients and doctors are paying close attention to its progress and look forward to its launch in China as soon as possible, bringing new treatment hope to more patients.